8-K: Establishment Labs Reports Strong Q4 2025, Positive 2026 Outlook

Establishment Labs Holdings Inc. announced robust fourth-quarter and full-year 2025 financial results, alongside optimistic revenue guidance for 2026 and 2027.

Summary

• Fourth quarter 2025 revenue reached $64.6 million, marking a 45.2% increase from the prior year period.
• Full year 2025 revenue totaled $211.1 million, an increase of 27.2% over 2024.
• Motiva U.S. revenue for the fourth quarter was $17.3 million, contributing to a full year U.S. revenue of $45.6 million.
• Net loss from operations for Q4 2025 significantly reduced by 79% to $3.9 million, compared to a $18.7 million loss in the year-ago period.
• Adjusted EBITDA for Q4 2025 turned positive at $5.5 million, an $18.6 million improvement from a $13.1 million loss in the prior year period.
• The cash balance as of December 31, 2025, was $75.6 million, an increase of $4.9 million from Q3 2025.
• The company provided 2026 revenue guidance of $264 million to $266 million, representing a 25.1% to 26.0% increase over 2025.
• Revenue growth for 2027 is projected to be at least 25%.
• Gross profit for Q4 2025 was $45.5 million, or 70.5% of revenue, an increase from 68.5% in Q4 2024.
• Total operating expenses for Q4 2025 were $49.5 million, a slight increase of $0.3 million compared to Q4 2024.
• SG&A expenses remained stable at $44.0 million in Q4 2025.
• R&D expenses increased by approximately $0.3 million to $5.4 million in Q4 2025, primarily due to personnel and regulatory costs.
• Net loss for Q4 2025 was $(2.615) million, a substantial improvement from $(34.531) million in Q4 2024.
• Net loss for the full year 2025 was $(51.064) million, compared to $(84.596) million in 2024.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive report, demonstrating strong revenue growth, significant improvement in profitability metrics (adjusted EBITDA), and clear guidance for continued expansion and future cash flow generation, indicating strong operational execution and market traction.

Positives

• Achieved strong revenue growth of 45.2% in Q4 2025 and 27.2% for the full year 2025.
• Significantly reduced net loss from operations by 79% in Q4 2025.
• Reported positive adjusted EBITDA of $5.5 million in Q4 2025, a substantial improvement from a loss in the prior year.
• Increased cash balance by $4.9 million from Q3 2025 to $75.6 million at year-end.
• Provided robust 2026 revenue guidance of $264 million to $266 million, indicating continued strong growth (25.1% to 26.0% increase).
• Projected at least 25% revenue growth for 2027, signaling sustained momentum.
• Improved gross profit margin to 70.5% in Q4 2025 from 68.5% in Q4 2024.
• Anticipates achieving its first quarter of positive cash flow in 2026 and full year positive cash flow in 2027.
• The Preserv product has been exceptionally well received globally, driving market expansion in both dollar and procedure volumes.
• The company is pioneering a new category of tissue-preserving and minimally invasive options, resonating with a new group of consumers.

Negatives

• Despite significant improvements, the company still reported a net loss of $2.6 million for Q4 2025 and $51.1 million for the full year 2025.
• The cash balance decreased by $14.8 million from December 31, 2024, although it increased from the prior quarter.
• Interest expense remains a notable cost, totaling $7.2 million in Q4 2025 and $25.3 million for the full year 2025.
• Total operating expenses saw a slight increase in Q4 2025 compared to the prior year.

Risks

• Ability to successfully, timely, and cost-effectively develop, seek and obtain regulatory clearance for, and commercialize product offerings.
• The rate of adoption of products by healthcare providers or other customers.
• The success of marketing initiatives.
• The safe and effective use of products.
• Ability to protect intellectual property.
• Future expansion plans and capital allocation.
• Ability to expand upon and/or secure sources of credit or capital.
• Ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in supply chains.
• Ability to attract and retain key personnel.
• Ability to scale operations to meet market demands.
• The effect on the business of existing and new regulatory requirements.
• Other economic and competitive factors.
• Operating in a very competitive and rapidly changing environment, with new risk factors emerging over time.

Future Outlook

The company projects 2026 revenue to be between $264 million and $266 million, representing a 25.1% to 26.0% increase over 2025. Furthermore, 2027 revenue growth is projected to be at least 25%. Management anticipates achieving its first quarter of positive cash flow in 2026 and a full year of positive cash flow in 2027, driven by strong demand for products like Preserv and operating leverage.

Management Comments

• "Our growth and momentum from 2025 has continued into 2026 with strong demand from both surgeons and patients."
• "Preserv has been exceptionally well received in markets around the globe, creating market expansion in both dollar and procedure volumes."
• "We have pioneered a new category of tissue-preserving and minimally invasive options which offer patients the benefits of minimal anesthesia and faster recovery. This is broadly resonating with a whole new group of consumers and driving meaningful growth for plastic surgery and Establishment Labs."
• "We delivered these results while maintaining strong financial discipline and achieving positive adjusted EBITDA over the second half of the year."
• "We are taking share while growing markets and expect topline growth to exceed 25% in both 2026 and 2027."
• "Our operating model is now displaying the significant leverage we have previously shared."
• "We are positioned for our first quarter of positive cash flow in 2026, and full year of positive cash flow in 2027."

Industry Context

StockSavvy.ai notes that Establishment Labs is actively shaping the breast aesthetics and reconstruction market by pioneering a new category of tissue-preserving and minimally invasive options, such as Preserv. This strategy appears to be resonating with a broader consumer base, driving market expansion and potentially capturing market share from traditional methods. The focus on minimal anesthesia and faster recovery aligns with broader healthcare trends towards less invasive procedures and improved patient experience.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, improved profitability, positive future guidance, and anticipated positive cash flow, potentially leading to increased share value.
• Employees: Continued growth and market expansion may lead to job stability and potential opportunities.
• Customers (Surgeons & Patients): Positive impact from the successful reception and expansion of innovative products like Preserv, offering new minimally invasive options.
• Creditors: Improved financial health and anticipated positive cash flow could enhance creditworthiness.
• Suppliers: Increased demand for products may lead to increased business for suppliers, though supply chain risks are noted.

Next Steps

• Host a conference call and webcast on February 24, 2026, at 8:30 a.m. Eastern Time to discuss financial results.
• File the company's annual report on Form 10-K on February 27, 2026.
• Continue to drive growth to exceed 25% in 2026 and 2027.
• Achieve the first quarter of positive cash flow in 2026.
• Achieve full year of positive cash flow in 2027.
• Continue development and commercialization of products including Mia Femtech, Preserv, GEM, Motiva Flora, and Zensor.

Key Dates

Recommendation

The company has demonstrated exceptional revenue growth, a significant turnaround in profitability with positive adjusted EBITDA, and a clear path to positive cash flow in the near future. The strong guidance for 2026 and 2027, coupled with the successful market reception of innovative products like Preserv, indicates robust operational momentum and market leadership in a growing segment. These factors suggest a strong investment opportunity.

Keywords

breast aesthetics, breast reconstruction, medical technology, Motiva, Preserv, Mia Femtech, financial results, Q4 2025, 2026 guidance, adjusted EBITDA, revenue growth, minimally invasive, womens health